|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
173,744,000 |
Market
Cap: |
1.07(B) |
Last
Volume: |
148,509 |
Avg
Vol: |
0 |
52
Week Range: |
$5.58 - $15.45 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 8.3 |
Insider 3/6 Months : 8.9 |
|
Guru Rank Number : 607 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focusing on developing the treatment of GI diseases. LINZESS® (linaclotide), Co.'s commercial product, is a product in a class of GI medicines called guanylate cyclase type C agonists and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is available to adult men and women suffering from IBS-C or CIC in the U.S. and Mexico and to adult men and women suffering from IBS-C in Japan and China. Co. has partnerships with pharmaceutical companies to support the development and commercialization of linaclotide.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
17,604 |
53,676 |
53,676 |
Total Buy Value |
$0 |
$160,420 |
$460,539 |
$460,539 |
Total People Bought |
0 |
2 |
2 |
2 |
Total Buy Transactions |
0 |
2 |
3 |
3 |
Total Shares Sold |
226,641 |
507,557 |
529,791 |
1,205,966 |
Total Sell Value |
$1,459,885 |
$5,741,044 |
$5,974,538 |
$13,645,593 |
Total People Sold |
6 |
7 |
8 |
11 |
Total Sell Transactions |
7 |
12 |
16 |
50 |
End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Walsh Christopher T Phd |
Director |
|
2015-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
16,556 |
46,270 |
|
- |
|
Olanoff Lawrence S |
Director |
|
2015-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
16,556 |
19,156 |
|
- |
|
Owens Edward P |
Director |
|
2015-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
16,556 |
134,006 |
|
- |
|
Mcguire Terrance |
Director |
|
2015-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
16,556 |
19,471 |
|
- |
|
Mchugh Julie |
Director |
|
2015-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
16,556 |
43,109 |
|
- |
|
Fanucci Marsha |
Director |
|
2015-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
16,556 |
36,334 |
|
- |
|
Conrades George N |
Director |
|
2015-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
16,556 |
62,221 |
|
- |
|
Olanoff Lawrence S |
Director |
|
2015-04-16 |
4 |
A |
$0.00 |
$0 |
D/D |
2,600 |
2,600 |
|
- |
|
Fanucci Marsha |
Director |
|
2015-03-18 |
4 |
AS |
$15.68 |
$491,396 |
D/D |
(31,339) |
19,778 |
|
- |
|
Hecht Peter M |
Chief Executive Officer |
|
2015-03-17 |
4 |
S |
$15.61 |
$1,953,154 |
D/D |
(125,000) |
4,141,417 |
|
- |
|
Hecht Peter M |
Chief Executive Officer |
|
2015-03-17 |
4 |
OE |
$1.56 |
$195,000 |
D/D |
125,000 |
4,266,417 |
|
- |
|
Consylman Gina |
Chief Accounting Officer |
|
2015-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
4,250 |
4,250 |
|
- |
|
Gilbert Halley E |
Chief Legal Officer |
|
2015-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
28,750 |
37,611 |
|
- |
|
Mccourt Thomas A |
Chief Commercial Officer |
|
2015-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
16,250 |
27,298 |
|
- |
|
Graney Thomas |
Chief Financial Officer |
|
2015-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
5,700 |
5,700 |
|
- |
|
Hecht Peter M |
Chief Executive Officer |
|
2015-03-16 |
4 |
S |
$15.60 |
$1,170,000 |
D/D |
(75,000) |
4,141,417 |
|
- |
|
Hecht Peter M |
Chief Executive Officer |
|
2015-03-16 |
4 |
OE |
$1.56 |
$117,000 |
D/D |
75,000 |
4,216,417 |
|
- |
|
Currie Mark G |
Chief Scientific Officer |
|
2015-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
21,875 |
26,098 |
|
- |
|
Walsh Christopher T Phd |
Director |
|
2015-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
165 |
29,714 |
|
- |
|
Ebersman David A |
Director |
|
2015-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
165 |
29,714 |
|
- |
|
Roberts Bryan E |
Director |
|
2015-03-13 |
4 |
A |
$15.07 |
$2,487 |
D/D |
165 |
15,250 |
|
- |
|
Cook Joseph C Jr |
Director |
|
2015-03-12 |
4 |
AS |
$15.54 |
$51,018 |
D/D |
(3,283) |
304,080 |
|
- |
|
Cook Joseph C Jr |
Director |
|
2015-03-11 |
4 |
AS |
$15.53 |
$40,378 |
D/D |
(2,600) |
43,975 |
|
- |
|
Roberts Bryan E |
Director |
|
2015-03-10 |
4 |
S |
$15.07 |
$1,355,429 |
I/I |
(89,350) |
0 |
|
- |
|
Roberts Bryan E |
Director |
|
2015-03-09 |
4 |
S |
$15.62 |
$103,907 |
I/I |
(6,648) |
6,975 |
|
- |
|
589 Records found
|
|
Page 21 of 24 |
|
|